Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies

Shivaani Kummar*, Martin E. Gutierrez, Erin R. Gardner, Xiaohong Chen, William D. Figg, Maria Zajac-Kaye, Min Chen, Seth M. Steinberg, Christine A. Muir, Mary Ann Yancey, Yvonne R. Horneffer, Lamin Juwara, Giovanni Melillo, S. Percy Ivy, Maria Merino, Len Neckers, Patricia S. Steeg, Barbara A. Conley, Giuseppe Giaccone, James H. DoroshowAnthony J. Murgo

*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

103 Scopus citations

Fingerprint

Dive into the research topics of 'Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies'. Together they form a unique fingerprint.

Medicine & Life Sciences